Trials / Completed
CompletedNCT00842088
Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease
A Randomized, Blinded, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 in Subjects With Sickle Cell Disease
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- HemaQuest Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 12 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of HQK-1001 administered for a total of 12 weeks (with one dosing break) in subjects with sickle cell disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Matching placebo capsule. Administered orally once a day on dosing days. |
| DRUG | HQK-1001 | HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days. |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2010-07-01
- First posted
- 2009-02-12
- Last updated
- 2011-08-01
Locations
9 sites across 2 countries: United States, Jamaica
Source: ClinicalTrials.gov record NCT00842088. Inclusion in this directory is not an endorsement.